Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

CDRH's Expedited Access Pathway: 17 Devices And Counting

This article was originally published in The Gray Sheet

Executive Summary

A system using nerve stimulation to treat diaphragm atrophy in mechanical ventilation patients is the latest product to be granted EAP designation. FDA officials recently confirmed that 17 devices have been accepted to the expedited development pathway about a year after the program launched.


Related Content

PDUFA VII Already: Could Breakthrough Ideas Apply Outside Program?
Senate Panel Passes Breakthrough Device, Other Measures; FDA Funding Debated
FDA Hopes To Balance Upfront Time Investment With Easier Reviews In New PMA Program


Related Companies